Compare Neurocrine Biosciences Inc (NBIX) vs VICI Properties Inc (VICI) Price & Performance

Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.

The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.

VICI Properties trades at $22.64, down 0.4% on the day, with a bearish technical outlook despite strong fundamentals. The REIT maintains exceptional profitability with 67.5% net margins and trades at attractive valuations (P/E 8.83, P/B 0.86). Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing, while the company continues expanding its tenant base through new lease agreements.

Wall Street remains bullish with 75% buy ratings and a $28.90 consensus target, representing 28% upside. Key risks include tenant concentration and rising interest rates, but the 7.8% dividend yield appears well-covered by strong cash flows. The current discount to NAV presents a compelling opportunity for income-focused investors.